0MGB
vs
O
OMX Copenhagen 25
0MGB
Over the past 12 months, 0MGB has outperformed OMX Copenhagen 25, delivering a return of +21% compared to OMX Copenhagen 25's +3% growth.
Stocks Performance
0MGB vs OMX Copenhagen 25
Performance Gap
0MGB vs OMX Copenhagen 25
Performance By Year
0MGB vs OMX Copenhagen 25
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Genmab A/S
Glance View
Genmab A/S is a biotechnology company that discovers and develops antibody medicines for cancer and other serious diseases. It does not make broad consumer products; instead, it focuses on turning lab-made antibodies into drug candidates that can be tested, approved, and sold by itself or with larger drugmakers. The company earns money in a few ways. It receives research funding and milestone payments from partners during development, then royalties or profit shares if a partnered drug reaches the market. Genmab also sells its own approved medicines in some markets, which gives it direct product revenue. Its main customers are not patients directly but pharmaceutical partners, hospitals, doctors, and ultimately patients who receive the finished medicines. Genmab stands out because it is built around antibody engineering and partnership deals, using big drug-company reach to bring complex biologic drugs from discovery to market.
